ArticleMedicine2026
Association of fat-related metabolic indices with MASLD and liver fibrosis: a cross-sectional analysis of NHANES 2017-2020.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The metabolic dysfunction-associated steatotic liver disease (MASLD) framework emphasizes the central role of metabolic disturbances in fatty liver disease. Fat-related metabolic indices integrate information on insulin resistance and adiposity; however, their associations with MASLD and hepatic fibrosis at the population level have not been fully elucidated. Thus, this study aimed to examine the associations of 6 fat-related metabolic indices with MASLD and liver fibrosis in a nationally representative U.S. population. We analyzed data from the National Health and Nutrition Examination Survey 2017-2020. Six fat-related metabolic indices: metabolic score for insulin resistance, metabolic score for visceral fat, cardiometabolic index, triglyceride-glucose index, waist triglyceride index, and lipid accumulation product, were calculated and categorized into quartiles. Hepatic steatosis and fibrosis were assessed using vibration-controlled transient elastography based on controlled attenuation parameter and liver stiffness measurement. Multivariable regression analyses were performed with progressive adjustment for potential confounders. All 6 indices exhibited significant dose-response associations with controlled attenuation parameter and MASLD prevalence. Higher quartiles were consistently associated with increased odds of MASLD after full adjustment. Positive associations with liver stiffness measurement and liver fibrosis were also observed, although the magnitude of associations was attenuated after comprehensive covariate adjustment. Among the indices, metabolic indices: metabolic score for insulin resistance, metabolic score for visceral fat, cardiometabolic index and lipid accumulation product demonstrated the strongest discriminative ability for liver fibrosis. Fat-related metabolic indices reflecting insulin resistance and adiposity are closely associated with MASLD and liver fibrosis in the general population, highlighting their relevance to metabolic liver disease phenotypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.